What's hot!

View all perspectives
What's Hot

Daily Recap - WEDNESDAY

Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?

Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

Bimekizumab in Active AS: 5 Year Study

Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

Cannabinoid Receptor in RA Patients

Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

Treatments in SpA

Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.

Watch video →

PR3+ in Lupus Nephritis

Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

Simulated Trials to Counter ORAL Survelliance

Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

Difficult to Treat axSpA

Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

Window of Opportunity in PsA

Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

TMP SMX Prophylaxis in GPA

Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

The FOREMOST Study: Apremilast in PsA

Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

The SMART Study: Split Dose Oral Methotrexate

Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.

Watch video →

Real World Experience with PEXIVAS Low Steroid Taper

Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →
38420215_s.jpg

Cancer and TNF inhibitors

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.

Read more →
ACR Best

#ACRbest Abstracts – Day 2

Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media.  Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more. 

Read more →

Effects of Apremilast on Cardiometabolic Effects in PsA

Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →

An Interview with Kevin Winthrop: Three Questions About COVID 19

Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.

Watch video →

Biologics as First-line Therapy for PMR and GCA?

Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.

Watch video →
      My blog just published on @rheumnow. We need to screen for CV dz, educate pts about CVD and work with cardiology colleag

      TheDaoIndex KDAO2011

      2 years 10 months ago
      My blog just published on @rheumnow. We need to screen for CV dz, educate pts about CVD and work with cardiology colleagues. https://t.co/XLc0YHtJ0B #ACR23
      Using deep neural network for spinal inflammation in axial SpA, the area under the curve of the receiver operating chara

      Dr. Antoni Chan

      2 years 10 months ago
      Using deep neural network for spinal inflammation in axial SpA, the area under the curve of the receiver operating characteristic (AUC-ROC) curve of the algorithm was 0.87±0.02, comparable with general radiologist Chan S et al Abst#1398 #ACR23 @RheumNow https://t.co/lrQRfc2RwN https://t.co/Fra8cDtQE5
      Long-term safety of risankizumab in PsA and PsO pts
      Over 5k pts, over 4 years
      Rates of AEs remained low
      malignancy inci

      Robert B Chao, MD

      2 years 10 months ago
      Long-term safety of risankizumab in PsA and PsO pts Over 5k pts, over 4 years Rates of AEs remained low malignancy incidence remains low @RheumNow #ACR23 Abs#1422 https://t.co/GBFke3XmQD
      @RheumNow So in GCA, we don’t know if therapies can truly disease modify at all. There’s a lot of grumbling disease,

      David Liew drdavidliew

      2 years 10 months ago
      @RheumNow So in GCA, we don’t know if therapies can truly disease modify at all. There’s a lot of grumbling disease, and it’s unclear whether we can stop long-term vascular issues. And in PMR, we have very little data on early therapy at all. So what’s the justification? #ACR23 @RheumNow https://t.co/spAMqfSOy2
      This is pretty nerdy, but I would love a documentary about filgotinib

      JAK class wins/fails feel highly idiosyncratic to

      Mike Putman EBRheum

      2 years 10 months ago
      This is pretty nerdy, but I would love a documentary about filgotinib JAK class wins/fails feel highly idiosyncratic to me The difference between UPA & FIL from science perspective seems negligible; financially, it's many billions of $$$ @rheumnow #ACR23 Abstr 1325 https://t.co/efGwSSrxz7
      #ACR23 @RheumNow #GreatDebate
      Treatment for PMR by Spiera
      - Plan rapid GC taper. It is OK to flare, prepare pt!
      - Low th

      Eric Dein

      2 years 10 months ago
      #ACR23 @RheumNow #GreatDebate Treatment for PMR by Spiera - Plan rapid GC taper. It is OK to flare, prepare pt! - Low threshold to introduce anti-IL-6 for GC intolerance or AEs No need for initial biologic treatment for PMR/GCA @philseo rebuttal upcoming... https://t.co/A0f3b0fMOr
      Should IL-6i be first line in GCA/PMR? Dr. Spiera says steroids work, are cheap; no evidence of using IL6i early in dise

      TheDaoIndex KDAO2011

      2 years 10 months ago
      Should IL-6i be first line in GCA/PMR? Dr. Spiera says steroids work, are cheap; no evidence of using IL6i early in disease. there had been cases where pts still had active vasculitis while on IL-6i. He starts with steroids first then add IL6i #GreatDebate #ACR23 @rheumnow https://t.co/Oq5Q9HFtW3
      #ACR23 #Debate Dr Spiera says NO need to up front use #glucocorticoid #sparing drugs in PMR - maybe only if flaring. Esp

      Janet Pope

      2 years 10 months ago
      #ACR23 #Debate Dr Spiera says NO need to up front use #glucocorticoid #sparing drugs in PMR - maybe only if flaring. Esp in PMR vs #GCA where maybe bDMARD in GCA in some Pts (my opinion) but for sure if failing #ACRbest #ACR23 @RheumNow @ACRheum https://t.co/Rt7rGZv3fW
      Towards Personalised Care in RA

      Since the millennium, we have seen an expansion in the number of advanced treatments bo

      Dr. John Cush RheumNow

      2 years 10 months ago
      Towards Personalised Care in RA Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). #ACR23 https://t.co/SjyfMyPyGw https://t.co/uzG72vKSpd
      RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by R

      Dr. John Cush RheumNow

      2 years 10 months ago
      RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
      #ACR23 Abs #0844 posterior element inflammation & facet joint ankylosis on MRI uncommon in r-axSpA patients. However

      Dr. Rachel Tate

      2 years 10 months ago
      #ACR23 Abs #0844 posterior element inflammation & facet joint ankylosis on MRI uncommon in r-axSpA patients. However, when FJ inflammation is present (vs w/o) the likelihood of developing facet joint ankylosis after 1 year is over 3 x higher. https://t.co/1Kln1pNH3p @rheumnow https://t.co/BatNTFfTG2
      Validation is needed, but SPARTAN + add'l stakeholders developed the first draft SPARTAN recommendations for referral of

      Dr. Rachel Tate

      2 years 10 months ago
      Validation is needed, but SPARTAN + add'l stakeholders developed the first draft SPARTAN recommendations for referral of adults with chronic back pain to a rheumatologist for evaluation of axSpA! Check out #ACR23 Abs #0841 https://t.co/ISv2lgHyka @rheumnow https://t.co/Qvy8LlzOw0
      When to use #belimumab and when to use #voclosporin? Dr. Dall'Era does the following:
      Belimumab: GFR<45, low proteinu

      TheDaoIndex KDAO2011

      2 years 10 months ago
      When to use #belimumab and when to use #voclosporin? Dr. Dall'Era does the following: Belimumab: GFR<45, low proteinuria, extrarenal dz, pt factors Voclosporin: GFR>45 w/o sig chronicity, high level proteinuria (3+g/), pt preference for oral #ACR23 #MeetExpert @rheumnow https://t.co/0SXRBtChfk
      "Get rid of partial response. Why would you want to see an oncologist who say I can get risk part of your cancer? Wouldn

      TheDaoIndex KDAO2011

      2 years 10 months ago
      "Get rid of partial response. Why would you want to see an oncologist who say I can get risk part of your cancer? Wouldn't you want to get rid of the whole cancer!" - Dr. M Petri on how we should view lupus nephritis #ACR23 @rheumnow #MeetExpert
      Proof of concept for cCAR BCMA CD19 - safely eliminated all autoabs, reset B cell/humoral immune system, & delivered

      Dr. Rachel Tate

      2 years 10 months ago
      Proof of concept for cCAR BCMA CD19 - safely eliminated all autoabs, reset B cell/humoral immune system, & delivered long-term, med-free remission in 1 dose in LN and SLE. More studies needed! #ACR Abs 1493 @rheumnow https://t.co/sT68cN3TKe

      Podcasts

      • Rheumatology Roundup
      • JAK - TYK2 Topic Panel
      • JAK - TYK2 Topic Panel

      Catch up on Conference Podcasts

      ×